机构:[1]Department of Hepatobiliary and Pancreatic Surgery, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Kunming, China.[2]Department of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.四川省人民医院四川省肿瘤医院[3]Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.
第一作者机构:[1]Department of Hepatobiliary and Pancreatic Surgery, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Kunming, China.[2]Department of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
共同第一作者:
通讯作者:
通讯机构:[1]Department of Hepatobiliary and Pancreatic Surgery, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Kunming, China.[*1]Department of Hepatobiliary and Pancreatic Surgery, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Kunming, China.
推荐引用方式(GB/T 7714):
Zhang Siyu,Ma Jun,Yu Tingdong,et al.circ_HMGCS1 modulates hepatocellular carcinoma chemoresistance via miR-338-5p/IL-7 pathway[J].JOURNAL OF CELLULAR AND MOLECULAR MEDICINE.2024,28(6):e18137.doi:10.1111/jcmm.18137.
APA:
Zhang Siyu,Ma Jun,Yu Tingdong,Song Zhengrui,Lau Wan Yee&Zha Yong.(2024).circ_HMGCS1 modulates hepatocellular carcinoma chemoresistance via miR-338-5p/IL-7 pathway.JOURNAL OF CELLULAR AND MOLECULAR MEDICINE,28,(6)
MLA:
Zhang Siyu,et al."circ_HMGCS1 modulates hepatocellular carcinoma chemoresistance via miR-338-5p/IL-7 pathway".JOURNAL OF CELLULAR AND MOLECULAR MEDICINE 28..6(2024):e18137